← All trials
NCT05830123
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 8, 2023
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2027
- First posted
- Apr 26, 2023
- Last posted
- Jul 20, 2023
- Enrollment
- 170
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Lead sponsor
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Peking UniversityOverall official - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Tianjin Medical UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Henan Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.